2018-12-08 07:06:50 Source: Shanghai Sponsorship News
On 7 December, the Shanghai Sunshine Applications Purchase Network delivered the results of "4 + 7" drug outputs. All 25 items received the application. Among them, Huahai Pharmaceutical's six drugs, such as hydrochloride paroxetine tablets, risperidone tablets and irbesartan hydrochlorothiazide tablets were selected. Jingxin Pharmaceutical Co., Ltd. selected Chooses of rosuvastatin calcium, tablets levetiracetam and benzene. Three drugs like tablet tricodipine sulfonate. In addition, compatible drugs are available by Xiansheng Pharmaceutical, Yangzijiang Pharmaceutical, Kelun Pharmaceutical and other medicinal companies. Amongst the international medicine companies, AstraZeneca and Bristol-Myers Squibb were only selected.
According to the reporter's comb, there are 6 types in bargaining connection, and is azithromycin, capsail amoxicillin, tramadol hydrochloride tablets, tablet apothecal Chongqing medicine and Katop of Pharmzhou. The sheets, injection of Hainan Puli de azithromycin.
The values of entecavir in Zhengdatian and atorvastatin fell in Beijing Jialin with over 90%. It is recognized that Zhengda Tianqing entecavir sold in 2017 3.169 billion yuan, with a market share of more than 40%; Beijing Jialin atorvastatin sales were sold over 2 billion yuan, with a market share of more than 20%.
The companies are reporting low prices, not only can they take a market share in a wild competition after that, benefit that moves to & # 39; The first time, but also they can contribute to new entrants. Journalists have told medicines companies that some of their profits were after the price change. After purchasing size, a department can be & # 39; market and product usage accordingly, and the company can still maintain a special growth rate.
The person believes that the medicinal companies are relevant at low prices to buy the species, which also have a choice. Supporting to maintain their banner status in the specialist area and its; make money from the product ports. For example, Zhengda Tianqing has rich produce lines in the field of liver diseases, and the conservation of rich produce in the echelon of continuous products. It has a market share of entecavir, which supports to & # 39; maintain the status of its first brand in the field of disease, and # 39; make money through specific materials and premium products in product ports.
However, some of the researchers said that the same price cuts will be shown in the company's revenue the following year. As a result of spreading tablets, eg example, the income yield of 1,736 billion yuan was received by the end of June 2018. Price was selected beforehand at a price of 0.62 yuan per piece, which is only 1/10 of the first price. It is a & # 39; expecting the significant drop in sales in the same period of 2019.
(Arctic store: Shanghai Securities News)